Literature DB >> 8302875

Humanization of murine monoclonal antibodies through variable domain resurfacing.

M A Roguska1, J T Pedersen, C A Keddy, A H Henry, S J Searle, J M Lambert, V S Goldmacher, W A Blättler, A R Rees, B C Guild.   

Abstract

Two murine monoclonal antibodies, N901 (anti-CD56) and anti-B4 (anti-CD19), were humanized by a process we call "resurfacing." A systematic analysis of known antibody structures has been used to determine the relative solvent accessibility distributions of amino acid residues in murine and human antibody variable (Fv) regions and has shown that the sequence alignment positions of surface amino acids for human and murine variable region heavy (VH) and light (VL) chains are conserved with 98% fidelity across species. While the amino acid usage at these surface positions creates surface residue patterns that are conserved within species, there are no identical patterns across species. However, surprisingly few amino acid changes need to be made to convert a murine Fv surface pattern to that characteristic of a human surface. Resurfacing was used to change the patterns of surface accessible residues in the Fv regions of the N901 and anti-B4 antibodies to resemble those found on the Fv regions of human antibody sequences. Two different procedures for selecting a human sequence were compared. For anti-B4, a data base of clonally derived human VL-VH sequence pairs was used, while for N901, sequences for VL and VH were independently selected from the Kabat et al. data base [Kabat, E. A., Wu, T. T., Reid-Miller, M., Perry, H. M. & Gottesman, K. S. (1991) Sequences of Proteins of Immunological Interest (DHHS, Washington, DC), 5th Ed.]. Resurfaced N901 and anti-B4 antibodies had apparent affinities for their cell surface ligands that were identical to those of their respective parent murine antibodies. These data provide evidence that, despite the differences in the surfaces of mouse and human Fv regions, it is possible to substitute one for the other while retaining full antigen binding affinity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8302875      PMCID: PMC521435          DOI: 10.1073/pnas.91.3.969

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Comparison of surface accessible residues in human and murine immunoglobulin Fv domains. Implication for humanization of murine antibodies.

Authors:  J T Pedersen; A H Henry; S J Searle; B C Guild; M Roguska; A R Rees
Journal:  J Mol Biol       Date:  1994-01-21       Impact factor: 5.469

2.  The Protein Data Bank: a computer-based archival file for macromolecular structures.

Authors:  F C Bernstein; T F Koetzle; G J Williams; E F Meyer; M D Brice; J R Rodgers; O Kennard; T Shimanouchi; M Tasumi
Journal:  J Mol Biol       Date:  1977-05-25       Impact factor: 5.469

3.  Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features.

Authors:  W Kabsch; C Sander
Journal:  Biopolymers       Date:  1983-12       Impact factor: 2.505

4.  Correlation between segmental mobility and the location of antigenic determinants in proteins.

Authors:  E Westhof; D Altschuh; D Moras; A C Bloomer; A Mondragon; A Klug; M H Van Regenmortel
Journal:  Nature       Date:  1984 Sep 13-19       Impact factor: 49.962

5.  Two-dimensional gel electrophoresis of serum specimens from patients with monoclonal gammopathies.

Authors:  R P Tracy; R M Currie; R A Kyle; D S Young
Journal:  Clin Chem       Date:  1982-04       Impact factor: 8.327

6.  Crystallographic refinement and atomic models of the intact immunoglobulin molecule Kol and its antigen-binding fragment at 3.0 A and 1.0 A resolution.

Authors:  M Marquart; J Deisenhofer; R Huber; W Palm
Journal:  J Mol Biol       Date:  1980-08-25       Impact factor: 5.469

7.  Characterization of an antigen expressed by human natural killer cells.

Authors:  J D Griffin; T Hercend; R Beveridge; S F Schlossman
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

8.  Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.

Authors:  S L Morrison; M J Johnson; L A Herzenberg; V T Oi
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

9.  One cell-one immunoglobulin. Origin of limited heterogeneity of myeloma proteins.

Authors:  Z L Awdeh; A R Williamson; B A Askonas
Journal:  Biochem J       Date:  1970-01       Impact factor: 3.857

10.  B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes.

Authors:  L M Nadler; K C Anderson; G Marti; M Bates; E Park; J F Daley; S F Schlossman
Journal:  J Immunol       Date:  1983-07       Impact factor: 5.422

View more
  44 in total

Review 1.  Generation of recombinant antibodies.

Authors:  S M Kipriyanov; M Little
Journal:  Mol Biotechnol       Date:  1999-09       Impact factor: 2.695

Review 2.  Generation and production of engineered antibodies.

Authors:  Sergey M Kipriyanov; Fabrice Le Gall
Journal:  Mol Biotechnol       Date:  2004-01       Impact factor: 2.695

Review 3.  Recombinant antibodies for the diagnosis and treatment of cancer.

Authors:  Jürgen Krauss
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

Review 4.  Molecular engineering of antibodies for therapeutic and diagnostic purposes.

Authors:  Frédéric Ducancel; Bruno H Muller
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

5.  Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies.

Authors:  Sue Townsend; Brian J Fennell; James R Apgar; Matthew Lambert; Barry McDonnell; Joanne Grant; Jason Wade; Edward Franklin; Niall Foy; Deirdre Ní Shúilleabháin; Conor Fields; Alfredo Darmanin-Sheehan; Amy King; Janet E Paulsen; Timothy P Hickling; Lioudmila Tchistiakova; Orla Cunningham; William J J Finlay
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-30       Impact factor: 11.205

6.  Antibody humanization by structure-based computational protein design.

Authors:  Yoonjoo Choi; Casey Hua; Charles L Sentman; Margaret E Ackerman; Chris Bailey-Kellogg
Journal:  MAbs       Date:  2015-08-07       Impact factor: 5.857

7.  Structural characterization of a recombinant monoclonal antibody by electrospray time-of-flight mass spectrometry.

Authors:  Lintao Wang; Godfrey Amphlett; John M Lambert; Walter Blättler; Wei Zhang
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

8.  Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry.

Authors:  Lintao Wang; Godfrey Amphlett; Walter A Blättler; John M Lambert; Wei Zhang
Journal:  Protein Sci       Date:  2005-08-04       Impact factor: 6.725

9.  Physiologically Based Modeling of the Pharmacokinetics of "Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal Antibodies in Colorectal Cancer Xenograft Mouse Models.

Authors:  Joseph Ryan Polli; Frank A Engler; Joseph P Balthasar
Journal:  J Pharm Sci       Date:  2018-10-12       Impact factor: 3.534

10.  A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models.

Authors:  Yanlan Yu; Pierre Lee; Yaohuang Ke; Yongke Zhang; Qiu Yu; Jonathan Lee; Mingzhen Li; Jialiang Song; Jungang Chen; Jihong Dai; Fernando Jose Rebelo Do Couto; Zhiqiang An; Weimin Zhu; Guo-Liang Yu
Journal:  PLoS One       Date:  2010-02-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.